Yahoo Finance

Goldman Sachs analyst Matthew Sykes lowered the firm’s price target on Danaher (DHR) to $240 from $260 but keeps a Buy rating on the shares after its Q1 results. The company’s Bioprocessing business continues to improve, and the current tariff headwind appears manageable, the analyst tells investors in a research note. Despite the top and bottom line beat in the quarter however, there is still merit in the prudent approach with Danaher maintaining prior FY25 guidance given all the moving parts around tariff implications and a challenging US Academic & Government end market, the firm adds.

Stay Ahead of the Market:

• Discover outperforming stocks and invest smarter with Top Smart Score Stocks.

• Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on DHR:

Disclaimer & DisclosureReport an Issue

• Danaher price target raised to $215 from $205 at Barclays

• Danaher price target lowered to $260 from $280 at JPMorgan

• Danaher’s Resilience and Strategic Positioning Drive Buy Rating Amid Growth Prospects

• Danaher price target lowered to $230 from $260 at Jefferies

• Morning Movers: Danaher gains and Northrop Grumman sinks after earnings